Roche Holding Newswire

Roche Holding Newswire

Comprehensive Real-Time News Feed for Roche Holding.

Results 1 - 20 of 27 in Roche Holding

  1. Roche holds hope for second test of Alzheimer's drugRead the original story w/Photo

    Jun 9, 2015 | Star Tribune

    Roche Holding is weighing a second test for an experimental Alzheimer's drug that failed in an initial study, after a similar offering from Biogen showed promise. Roche stopped a trial of gantenerumab in December because patients weren't benefiting more than those receiving a placebo.

    Comment?

  2. Roche Holding Cut to Sell at ZacksRead the original story

    Jun 9, 2015 | AmericanBankingNews.com

    ... competition in the DME and wet AMD space. Generics are expected to impact top-line growth in 2015." Shares of Roche Holding ( OTCMKTS:RHHBY ) traded down 1.38% on Tuesday, hitting $35.76. 2,017,137 shares of the company's stock traded hands. Roche ...

    Comment?

  3. Roche takes another shot at Alzheimer's drugRead the original story w/Photo

    Jun 9, 2015 | Salt Lake Tribune

    Geneva a Roche Holding is weighing a second test for an experimental Alzheimer's drug that failed in an initial study, after a similar offering from Biogen showed promise in slowing the memory-robbing ailment. Roche stopped a trial of gantenerumab in December because patients weren't benefiting more than those receiving a placebo.

    Comment?

  4. Roche Holding Given Average Rating of "Hold" by AnalystsRead the original story

    May 27, 2015 | AmericanBankingNews.com

    Shares of Roche Holding have received a consensus rating of "Hold" from the seven analysts that are currently covering the company, American Banking & Market News reports . One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company.

    Comment?

  5. Roche Holding Now Covered by Analysts at Erste GroupRead the original story

    May 22, 2015 | AmericanBankingNews.com

    ... A number of other analysts have also recently weighed in on RHHBY. Analysts at Zacks downgraded shares of Roche Holding from a "hold" rating to a "sell" rating and set a $31.00 price target on the stock in a research note on Tuesday, March 24th. ...

    Comment?

  6. Roche nominates Smith & Nephew CFO to boardRead the original story w/Photo

    May 8, 2015 | MarketWatch

    Roche Holding AG said Friday it was nominating the chief financial officer of medical equipment maker Smith & Nephew PLC to its board of directors after long-serving member Dame DeAnne Julius chose not to run for re-election. Basel-based Roche said its board had nominated Julie Brown to replace Dame Julius, who has served since 2002.

    Comment?

  7. Roche sales rise, lifted by cancer drugsRead the original story w/Photo

    Apr 22, 2015 | MarketWatch

    Roche Holding AG said strong growth of its core cancer franchise pushed sales 3% higher in the first quarter, prompting the Swiss drug giant to confirm its guidance for the year and suggest it will raise its dividend. Basel-based Roche said sales rose to 11.83 billion Swiss francs in the quarter ended March 31, beating an analyst forecast of 11.508 billion francs.

    Comment?

  8. Roche Holding Given Consensus Rating of "Hold" by AnalystsRead the original story

    Apr 20, 2015 | AmericanBankingNews.com

    Shares of Roche Holding have received a consensus rating of "Hold" from the six brokerages that are presently covering the stock, Analyst Ratings Network.com reports . One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company.

    Comment?

  9. Medtronic PLC (MDT), AbbVie Inc. (ABBV), Humana Inc (HUM): Rock...Read the original story

    Apr 14, 2015 | Insider Monkey

    ... ITMN ), which had a monumental 2014, gaining nearly 400% on the year leading up to and following its sale to Roche Holding Ltd. (ADR) (OTCMKTS: RHHBY ). We are very interested in the 13F filings of funds like Rock Springs, as we use them to ...

    Comment?

  10. Roche's Avastin cancer drug gets European approvalRead the original story w/Photo

    Apr 8, 2015 | MarketWatch

    European regulators approved Roche Holding AG's Avastin in combination with chemotherapy for treating women with advanced cervical cancer, the Swiss pharmaceutical giant said Wednesday, expanding the range of cancers the drug can be used to treat. Basel-based Roche said the European Commission approved the expanded use of the drug based on a study that showed the combination of Avastin and chemotherapy resulted in patients living almost four months longer than women receiving chemotherapy alone.

    Comment?

  11. Roche Holding Given Consensus Recommendation of "Hold" by AnalystsRead the original story

    Feb 19, 2015 | AmericanBankingNews.com

    Shares of Roche Holding have received a consensus rating of "Hold" from the five ratings firms that are presently covering the company, Analyst RN reports . Three research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company.

    Comment?

  12. Roche Says Swiss Franc's Surge May Erode Profit Growth This YearRead the original story

    Jan 28, 2015 | The Washington Post

    Roche Holding AG, the world's largest seller of cancer drugs, said the Swiss franc's surge may strip 9 percentage points from growth in operating profit this year. The currency's strength will probably pare 6 percentage points from sales growth, based on the average exchange rate for January, Chief Financial Officer Alan Hippe said at a press conference in Basel today.

    Comment?

  13. Roche Sees Profit, Sales IncreasingRead the original story w/Photo

    Jan 28, 2015 | Wall Street Journal

    Roche Holding AG posted a 16% drop in annual profit as the Swiss drug maker booked large impairments and restructured its debt, but the company said Wednesday it expects sales and profit to increase this year. Basel-based Roche said sales are expected to grow in low- to mid-single digits in 2015, when stripping out the effect of foreign-currency exchange rate fluctuations.

    Comment?

  14. Apple's Earnings Report Looks Optimistic: MunsterRead the original story w/Photo

    Jan 27, 2015 | Bloomberg

    Jan. 27 -- Piper Jaffray's Gene Munster discusses Apple's fiscal first-quarter profit with Bloomberg's Cory Johnson on "Bloomberg West." Jan. 28 -- Cancer drug Kadcyla "will remain a very important growth driver," said Roche Holding AG Chief Executive Officer Severin Schwan in an interview with Manus Cranny on Bloomberg Television's "Countdown" from Basel.

    Comment?

  15. Roche misses forecasts as costs riseRead the original story w/Photo

    Jan 27, 2015 | MarketWatch

    Swiss drug maker Roche Holding AG said Wednesday that its full-year net income fell 16% despite rising sales of its cancer treatments. Basel-based Roche said net income attributable to shareholders fell to 9.33 billion Swiss francs from 11.16 billion francs a year earlier, missing analysts' forecasts of 11.54 billion francs.

    Comment?

  16. Roche Profit Misses ForecastsRead the original story w/Photo

    Jan 27, 2015 | Wall Street Journal

    Swiss drug maker Roche Holding AG said Wednesday that its full-year net income fell 16% despite rising sales of its cancer treatments. Basel-based Roche said net income attributable to shareholders fell to 9.33 billion Swiss francs from 11.16 billion francs a year earlier, missing analysts' forecasts of 11.54 billion francs.

    Comment?

  17. Roche Holding acquiring majority stake in US firm Foundation MedicineRead the original story w/Photo

    Jan 12, 2015 | Big News Network.com

    ... is administered by Mainstream Media EC on behalf of Big News Network. BASEL Swiss global healthcare company Roche Holding is acquiring majority stake of up to 56.3 percent in US- based Foundation Medicine (FMI) for up to $1.18 billion to promote ...

    Comment?

  18. Roche to buy $1B stake in genomics companyRead the original story w/Photo

    Jan 12, 2015 | Salt Lake Tribune

    San Francisco a Roche Holding plans to pay more than $1 billion for a majority stake in Foundation Medicine Inc. to get access to genomic tests for screening tumors and to develop a new generation of treatments for fighting cancer. Roche will buy 5 million new shares of Cambridge, Mass.-based Foundation for $50 each and make an offer to purchase stock from existing investors for the same price to take its stake to as much as 56 percent, the companies said in a statement Monday.

    Comment?

  19. Switzerland's Roche Holding and AC Immune strike U.S. dealsRead the original story w/Photo

    Jan 12, 2015 | TheStreet.com

    ... registration. Two Swiss pharmaeutical companies were at the center of Monday's drug company buying binge with Roche Holding AG hoping to buy control of Cambridge, Mass.-based Foundation Medicine Inc. From Basel, Roche said it would offer to buy ...

    Comment?

  20. Roche to buy majority stake in FoundationRead the original story w/Photo

    Jan 12, 2015 | RTE.ie

    Roche Holding will acquire a majority stake in molecular and genomic analysis firm Foundation Medicine for up to $1.18 billion, it said today. This targeted approach to treating disease is gaining traction in many medical fields and is attractive to governments and insurers who pay for healthcare, since it means that drugs should go only to patients who are likely to benefit.

    Comment?